Adrenal Function in GHD Children

Growth Hormone Treatment Clinical Trial

Official title: Evaluation of Adrenal Function Before and After GH Treatment in GHD Affected by GH Deficiency

Status Completed

Clinical Trial Summary

To evaluate in children affected by idiopathic GHD the adrenal function both at baseline and after 6 and 12 months of GH treatment.

Clinical Trial Description

The relationship between the growth hormone (GH)-insulin like growth factor (IGF)-I system and the hypothalamic-pituitary-adrenal (HPA) axis is complex and not univocal. Both a stimulatory and neutral effect of IGF-I on HPA axis has been demonstrated in in vitro models and in healthy subjects, respectively. The effect of GH on the 11beta-hydroxysteroid dehydrogenases (11beta-HSD) isozymes is always to be considered in patients affected by GHD both at diagnosis and during GH treatment. Indeed, in peripheral tissues, corticosteroid hormone action is partially determined by the activity of 11beta-HSD, two isozymes of which interconvert hormonally active cortisol and inactive cortisone. 11beta-HSD2 inactivates cortisol to cortisone in the kidney, whilst 11beta-HSD1 performs the reverse reaction activating cortisol from cortisone in the liver and adipose tissue.

For these reasons, many data are available about the evaluation of adrenal function in patients affeceted byGHD, but most of them come from patients with organic GHD or adult patients, while few and discordant data are available on pediatric GHD patients. We aimed to evaluate, through insulin tolerance test, the adrenal function in about 30 children with overt diagnosis of idiopathic GHD both at baseline and after 6 and 12 months of GH treatment. ;

Related Conditions & MeSH terms

• Adrenal; Functional Disturbance
• Growth Hormone Treatment
• Pathologic Processes

• NCT number: NCT03203356
• Study type: Observational
• Source: University of Palermo
• Status: Completed
• Phase: N/A
• Start date: May 30, 2016
• Completion date: May 30, 2017